Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

753 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.
Ansari A, Satalkar S, Patil V, Shete AS, Kaur S, Gupta A, Singh S, Raja M, Severance DL, Bernales S, Chakravarty S, Hung DT, Pham SM, Herrera FJ, Rai R. Ansari A, et al. Among authors: chakravarty s. Bioorg Med Chem Lett. 2017 Jan 15;27(2):217-222. doi: 10.1016/j.bmcl.2016.11.080. Epub 2016 Nov 25. Bioorg Med Chem Lett. 2017. PMID: 27923618
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Jadhavar PS, Ramachandran SA, Riquelme E, Gupta A, Quinn KP, Shivakumar D, Ray S, Zende D, Nayak AK, Miglani SK, Sathe BD, Raja M, Farias O, Alfaro I, Belmar S, Guerrero J, Bernales S, Chakravarty S, Hung DT, Lindquist JN, Rai R. Jadhavar PS, et al. Among authors: chakravarty s. Bioorg Med Chem Lett. 2016 Nov 1;26(21):5222-5228. doi: 10.1016/j.bmcl.2016.09.058. Epub 2016 Oct 4. Bioorg Med Chem Lett. 2016. PMID: 27717544
Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ.
Pujala B, Agarwal AK, Middya S, Banerjee M, Surya A, Nayak AK, Gupta A, Khare S, Guguloth R, Randive NA, Shinde BU, Thakur A, Patel DI, Raja M, Green MJ, Alfaro J, Avila P, Pérez de Arce F, Almirez RG, Kanno S, Bernales S, Hung DT, Chakravarty S, McCullagh E, Quinn KP, Rai R, Pham SM. Pujala B, et al. Among authors: chakravarty s. ACS Med Chem Lett. 2016 Oct 28;7(12):1161-1166. doi: 10.1021/acsmedchemlett.6b00356. eCollection 2016 Dec 8. ACS Med Chem Lett. 2016. PMID: 27994757 Free PMC article.
Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors.
Ramachandran SA, Jadhavar PS, Miglani SK, Singh MP, Kalane DP, Agarwal AK, Sathe BD, Mukherjee K, Gupta A, Haldar S, Raja M, Singh S, Pham SM, Chakravarty S, Quinn K, Belmar S, Alfaro IE, Higgs C, Bernales S, Herrera FJ, Rai R. Ramachandran SA, et al. Among authors: chakravarty s. Bioorg Med Chem Lett. 2017 May 15;27(10):2153-2160. doi: 10.1016/j.bmcl.2017.03.064. Epub 2017 Mar 24. Bioorg Med Chem Lett. 2017. PMID: 28377059
Discovery of MDV6058 (PF-06952229), a selective and potent TGFβR1 inhibitor: Design, synthesis and optimization.
Pujala B, Ramachandran SA, Sonawane M, Kamble MM, Panpatil D, Adhikari S, Soni S, Subbareddy V, Shinde BU, Nayak AK, Bansal C, Gupta A, Mukherjee K, Agarwal AK, Guerrero J, Herrera FJ, Bernales S, Guha M, Chakravarty S, Pham SM, Rai R. Pujala B, et al. Among authors: chakravarty s. Bioorg Med Chem Lett. 2022 Nov 1;75:128979. doi: 10.1016/j.bmcl.2022.128979. Epub 2022 Sep 8. Bioorg Med Chem Lett. 2022. PMID: 36089110
Temozolomide analogs with improved brain/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomide.
Rai R, Banerjee M, Wong DH, McCullagh E, Gupta A, Tripathi S, Riquelme E, Jangir R, Yadav S, Raja M, Melkani P, Dixit V, Patil U, Shrivastava R, Middya S, Olivares F, Guerrero J, Surya A, Pham SM, Bernales S, Protter AA, Hung DT, Chakravarty S. Rai R, et al. Among authors: chakravarty s. Bioorg Med Chem Lett. 2016 Oct 15;26(20):5103-5109. doi: 10.1016/j.bmcl.2016.08.064. Epub 2016 Aug 21. Bioorg Med Chem Lett. 2016. PMID: 27614414
Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat Non-Hodgkin's B Cell Malignancies.
Alfaro J, Pérez de Arce F, Belmar S, Fuentealba G, Avila P, Ureta G, Flores C, Acuña C, Delgado L, Gaete D, Pujala B, Barde A, Nayak AK, Upendra TVR, Patel D, Chauhan S, Sharma VK, Kanno S, Almirez RG, Hung DT, Chakravarty S, Rai R, Bernales S, Quinn KP, Pham SM, McCullagh E. Alfaro J, et al. Among authors: chakravarty s. J Pharmacol Exp Ther. 2017 May;361(2):312-321. doi: 10.1124/jpet.116.238022. Epub 2017 Mar 15. J Pharmacol Exp Ther. 2017. PMID: 28298527
Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles.
Tan X, Tester RW, Luedtke GR, Chakravarty S, Mavunkel BJ, Perumattam JJ, Lu Q, Nashashibi I, Jung J, Hu J, Liclican A, Almirez R, Tabora J, Tran V, Laney M, Levy DE, Dugar S. Tan X, et al. Among authors: chakravarty s. Bioorg Med Chem Lett. 2010 Feb 1;20(3):828-31. doi: 10.1016/j.bmcl.2009.12.091. Epub 2010 Jan 4. Bioorg Med Chem Lett. 2010. PMID: 20071169
Piperidine-based heterocyclic oxalyl amides as potent p38 alpha MAP kinase inhibitors.
Mavunkel BJ, Perumattam JJ, Tan X, Luedtke GR, Lu Q, Lim D, Kizer D, Dugar S, Chakravarty S, Xu YJ, Jung J, Liclican A, Levy DE, Tabora J. Mavunkel BJ, et al. Among authors: chakravarty s. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1059-62. doi: 10.1016/j.bmcl.2009.12.031. Epub 2009 Dec 11. Bioorg Med Chem Lett. 2010. PMID: 20031411
753 results